Aura Biosciences’ EPS Estimate Up 5.9%, YTD Return 2.2%
Aura Biosciences has gained 2.2% year-to-date while its consensus current-year EPS estimate rose 5.9% over the past three months, reflecting improved analyst sentiment. The stock holds a Zacks Rank #2 (Buy) within the Medical – Biomedical and Genetics industry, which ranks #88 and has advanced 8% this year.
1. Year-to-Date Performance
Aura Biosciences has delivered a 2.2% gain since the start of the calendar year, outperforming the broader Medical sector’s 1.9% increase but lagging the Medical – Biomedical and Genetics industry’s 8% rise.
2. EPS Estimate Revisions
Analysts have lifted the consensus current-year EPS estimate by 5.9% over the last three months, indicating stronger expected profitability and growing confidence in the company’s financial outlook.
3. Zacks Rank and Industry Context
The stock holds a Zacks Rank #2 (Buy), reflecting positive earnings estimate revisions, and competes within a 447-stock Medical – Biomedical and Genetics industry that ranks #88 among 16 groups and has advanced 8% year-to-date.